Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Aug 11, 2026
Zoom Communications (ZM) Delivers +19.4% Surge on Earnings and AI Momentum

Zoom Communications (ZM) Delivers +19.4% Surge on Earnings and AI Momentum

Key Takeaways

  • Zoom Communications (ZM) surged approximately 19.4% over the last 30 days, climbing from $89.76 on July 10 to $107.20 as of August 10, 2026.
  • The rally was fueled by a powerful combination of strong Q1 FY2027 earnings, raised full-year guidance, and accelerating AI product adoption across the enterprise customer base.
  • Institutional accumulation intensified, with Bank of America increasing its stake by 50.5% and unusually high call options activity signaling bullish sentiment.
  • Over the broader quarter, the stock proved highly volatile — plunging to $82.88 in late June before staging a sharp recovery, ending roughly flat compared to mid-May levels.
  • Investors are now focused on the upcoming Q2 FY2027 earnings report expected on August 25, 2026, as the next major catalyst.

Zoom Communications (ZM) Company Overview and Market Position

Zoom Communications, Inc. is a leading provider of cloud-based unified communications and collaboration solutions. The company's platform encompasses video conferencing, voice calling, instant messaging, webinars, and contact center capabilities, serving enterprises, educational institutions, government agencies, and individual users worldwide. Founded in 2011 by Eric S. Yuan and headquartered in San Jose, California, Zoom has evolved from a video-meeting pioneer into an AI-first work platform. Its product portfolio now includes Zoom Meetings, Zoom Phone, Zoom Contact Center, Zoom Rooms, and AI-powered tools such as AI Companion and ZoomMate. With trailing twelve-month revenue of approximately $4.9 billion and a market capitalization near $31 billion, Zoom competes with larger ecosystem players like MSFT and CRM while maintaining a reputation for ease of use and reliability. The company's expanding enterprise segment — now representing 60% of total revenue — and its AI monetization strategy are central to the investment narrative. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Zoom Communications (ZM) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, ZM stock delivered a standout gain of approximately 19.4%, rising from a closing price of $89.76 on July 10, 2026, to $107.20 on August 10, 2026. The advance was broad-based, with the stock posting gains in 12 of the last 20 trading sessions and breaking decisively above both its 50-day simple moving average of roughly $92.53 and its 200-day moving average of approximately $89.76.

The quarterly picture reveals a far more turbulent journey. In mid-May 2026, ZM traded near $107 following a strong Q1 earnings beat. The stock then succumbed to a macro-driven technology sell-off in June, triggered in part by a reinstated U.S. naval blockade on Iran that pushed Brent crude above $85 per barrel and intensified rate-hike concerns. ZM bottomed at $82.88 on June 25 — a decline of roughly 22.6% from its quarterly peak — before staging a sustained recovery through July and early August. Over the full quarter, the stock is essentially flat, but the round trip underscores the elevated volatility that has defined ZM's recent trading pattern. From what I see, the moving average breakouts here are worth monitoring closely.

What Drove ZM Stock Price in the Last 30 Days

Several converging catalysts powered ZM's 19.4% surge. The most important was the lasting tailwind from the company's Q1 FY2027 earnings report released on May 21, which continued to resonate with investors. Zoom posted adjusted earnings per share of $1.55, handily beating the consensus estimate of $1.42, while revenue of $1.24 billion exceeded the $1.22 billion forecast. Enterprise revenue grew 7.2% year-over-year to $755.7 million, and the company raised its full-year FY2027 guidance to $5.96–$6.00 in adjusted EPS — well above the then-consensus of $5.87.

The AI narrative gained significant traction. Zoom reported that paid monthly active users of AI Companion grew 184% year-over-year. The company launched ZoomMate, an AI assistant integrating with CRM, Jira, and Slack at $20 per user per month, and unveiled a standalone Virtual Agent Receptionist. These moves reinforced the view that Zoom is successfully monetizing AI beyond its core meeting software.

Institutional conviction strengthened markedly. Bank of America increased its ZM position by 50.5%, adding 592,899 shares to reach 1.77 million shares worth approximately $142 million. Pacer Advisors boosted its stake by 10.8% to 2.6 million shares. Allianz Asset Management raised its holdings by 15.6%. Meanwhile, options trading activity turned unusually bullish — call option volume surged to 32,087 contracts, roughly 73% above the daily average, with the put/call ratio falling to 0.07. Multiple analysts raised price targets following the Q1 report, including Benchmark ($125), BTIG ($125), Citigroup ($126), RBC ($130), and Wells Fargo ($105).

It is worth noting that insider selling occurred during this period — CEO Eric Yuan sold 12,100 shares at an average of $100.17 and Director Santiago Subotovsky sold 7,911 shares at approximately $101.33 — but all transactions were executed under pre-arranged Rule 10b5-1 trading plans and did not appear to dampen market enthusiasm. I’m watching this closely for any shifts in institutional flows.

What Drove ZM Stock Performance Over the Last Quarter

Zoom's quarterly performance was defined by two opposing forces: powerful company-specific momentum and a punishing macro-driven sell-off. After peaking near $111 in early June following the Q1 earnings beat, the stock was caught in a broad technology rout. The oil shock from renewed U.S.-Iran tensions pushed the Federal Reserve to maintain rates in the 3.50%–3.75% range, raising the cost of capital for growth-oriented software stocks. ZM plunged to $82.88 by June 25 before sentiment shifted.

The recovery phase, which began in late June and accelerated through July and early August, was propelled by the same fundamental strengths that drove the 30-day rally: AI monetization progress, strong enterprise metrics, aggressive share buybacks — the board authorized an additional $1 billion repurchase program, supplementing $625 million remaining from a prior authorization — and a healthy balance sheet with $7.72 billion in net cash. The quarter also featured Zoom's definitive agreement to acquire Common Room, an AI-powered sales intelligence platform, and a leadership reshuffle that named Carlos Quaderi as Head of Asia Pacific, signaling international expansion ambitions. Despite ending the quarter roughly flat, the violent V-shaped recovery demonstrated the market's willingness to reward Zoom's AI-driven transformation story when macro headwinds ease. One thing that stands out is how quickly sentiment reversed once the macro pressure eased.

ZM Stock Forecast Drivers: What Investors Should Watch Next

The most immediate catalyst on the horizon is Zoom's Q2 FY2027 earnings report, expected on August 25, 2026. Analysts are projecting EPS of $1.38 on revenue of $1.27 billion, and investors will scrutinize enterprise revenue growth, AI Companion adoption trends, and any updates to full-year guidance. Beyond earnings, key factors include the pace of AI monetization — particularly the uptake of ZoomMate and Contact Center Elite — and the company's ability to sustain margin expansion while investing in AI infrastructure. Macroeconomic conditions also loom large; persistent inflation, elevated interest rates, or further geopolitical disruptions could weigh on software valuations broadly. Competitive dynamics from MSFT Teams and CRM in the contact center space remain an ongoing narrative. Additionally, the potential for Zoom's early-stage investment in Anthropic to yield returns through a future IPO represents an underappreciated wildcard. As always, investors should monitor institutional ownership filings and insider transaction patterns for signals about long-term conviction. I also checked this using Tickeron’s AI Trend Prediction Engine to gauge potential price movements.

Exploring Tickeron’s Trending AI Robots

In my analysis of volatile names like ZM, I often review Tickeron’s Trending AI Robots to see how algorithmic strategies are performing across similar equities. This page highlights top bots with transparent metrics and histories, helping align data-driven approaches with my own research process.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ZM

Momentum Indicator for ZM turns positive, indicating new upward trend

ZM saw its Momentum Indicator move above the 0 level on July 31, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for ZM just turned positive on July 27, 2026. Looking at past instances where ZM's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .

ZM moved above its 50-day moving average on July 31, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ZM crossed bullishly above the 50-day moving average on August 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ZM advanced for three days, in of 290 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 186 cases where ZM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ZM broke above its upper Bollinger Band on August 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ZM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.153) is normal, around the industry mean (28.441). P/E Ratio (15.788) is within average values for comparable stocks, (81.498). ZM's Projected Growth (PEG Ratio) (4.214) is slightly higher than the industry average of (1.723). Dividend Yield (0.000) settles around the average of (0.048) among similar stocks. P/S Ratio (6.609) is also within normal values, averaging (69.431).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

Notable companies

The most notable companies in this group are Shopify Inc (NASDAQ:SHOP), Salesforce (NYSE:CRM), Uber Technologies (NYSE:UBER), ServiceNow Inc. (NYSE:NOW), Adobe (NASDAQ:ADBE), Datadog (NASDAQ:DDOG), Intuit (NASDAQ:INTU), Autodesk (NASDAQ:ADSK), Workday (NASDAQ:WDAY), Atlassian Corp (NASDAQ:TEAM).

Industry description

Packaged software comprises multiple software programs bundled together and sold as a group. For example, Microsoft Office includes multiple applications such as Excel, Word, and PowerPoint. In some cases, buying a bundled product is cheaper than purchasing each item individually[s20] . Microsoft Corporation, Oracle Corp. and Adobe are some major American packaged software makers.

Market Cap

The average market capitalization across the Packaged Software Industry is 10.35B. The market cap for tickers in the group ranges from 291 to 237.4B. SAP holds the highest valuation in this group at 237.4B. The lowest valued company is BLGI at 291.

High and low price notable news

The average weekly price growth across all stocks in the Packaged Software Industry was 1%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 10%. YXT experienced the highest price growth at 117%, while NXTT experienced the biggest fall at -100%.

Volume

The average weekly volume growth across all stocks in the Packaged Software Industry was 1%. For the same stocks of the Industry, the average monthly volume growth was 32% and the average quarterly volume growth was -54%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 77
Price Growth Rating: 57
SMR Rating: 78
Profit Risk Rating: 94
Seasonality Score: -3 (-100 ... +100)
View a ticker or compare two or three
ZM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a developer of video-first communications platform and application

Industry PackagedSoftware

Profile
Details
Industry
Packaged Software
Address
55 Almaden Boulevard
Phone
+1 888 799-9666
Employees
7420
Web
https://www.zoom.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.